The company, Blueprint Medicines, has provided their evidence submission which is being reviewed by the External Academic Group, Centre for Reviews and Dissemination and Centre for Health Economics – York. To ensure that the committee gets the best evidence package possible, this will no longer be discussed at the committee meeting on 2 July 2024. The second committee meeting discussion will be rearranged, and we will update all stakeholders with the new date in due course.